Pain Management in Children and Young Adults With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 7, 2013

Primary Completion Date

January 3, 2018

Study Completion Date

January 3, 2018

Conditions
Sickle Cell Disease
Interventions
DRUG

Gabapentin

Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.

DRUG

Placebo

Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

"Scan

UNKNOWN

lead

St. Jude Children's Research Hospital

OTHER

NCT01954927 - Pain Management in Children and Young Adults With Sickle Cell Disease | Biotech Hunter | Biotech Hunter